Company argenx SE

Equities

ARGX

NL0010832176

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles Other stock markets 16:55:00 15/12/2025 GMT			5-day change	1st Jan Change
723.60 ^EUR	-3.93%		-7.66%	+20.60%

12-15	ARGENX : Gets a Buy rating from Jefferies	ZD
12-15	European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading	MT

Business description: argenx SE

argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.

Number of employees: 1,599

Sales by Activity: argenx SE

Fiscal Period: December	2020	2021	2022	2023	2024
Biotechnology	54.53M	528M	441M	1.27B	2.25B

See all business segments

Geographical breakdown of sales: argenx SE

Fiscal Period: December	2020	2021	2022	2023	2024
United States	36.13M	317M	378M	1.08B	1.9B
Rest of The World	-	-	-	-	161M
Japan	-	-	15.76M	56.43M	89.39M
China	-	178M	4.24M	20.44M	43.52M
Netherlands	-	-	-	-	153K
EMEA	-	-	-	72.85M	-
Europe	-	-	5.68M	-	-
Other	-	123K	2.04M	-	-
Denmark	299K	1.39M	5.36M	-	-

See all geographic segments

Executive Committee: argenx SE

Manager	Title	Age	Since
Tim van Hauwermeiren CEO	Chief Executive Officer	53	14/07/2008
Karl Gubitz DFI	Director of Finance/CFO	55	31/05/2021
Filip Borgions CTO	Chief Tech/Sci/R&D Officer	-	31/12/2014
Karen Massey COO	Chief Operating Officer	46	12/03/2023
Peter Ulrichts CTO	Chief Tech/Sci/R&D Officer	45	31/12/2022

See ARGENX SE governance

Composition of the Board of Directors: argenx SE

Director	Title	Age	Since
Tim van Hauwermeiren BRD	Director/Board Member	53	30/06/2014
Peter K. M. Verhaeghe CHM	Chairman	67	14/10/2008
Joseph deBethizy BRD	Director/Board Member	75	12/05/2015
Pamela Klein BRD	Director/Board Member	64	27/04/2016
Anthony Adam Rosenberg BRD	Director/Board Member	71	25/04/2017
James Daly BRD	Director/Board Member	63	07/05/2018
Camilla Sylvest BRD	Director/Board Member	53	07/09/2022
Steve Krognes BRD	Director/Board Member	56	26/02/2023
Ana Cespedes BRD	Director/Board Member	52	11/12/2022
Brian Kotzin BRD	Director/Board Member	75	06/05/2024

Composition of the Board of Directors

Shareholders: argenx SE

Name	Equities	%	Valuation
Wellington Management Co. LLP 2.955 %	1,819,494	2.955 %	1 652 M €
Norges Bank Investment Management 2.718 %	1,673,386	2.718 %	1 519 M €
Capital Research & Management Co. (World Investors) 0.3337 %	205,430	0.3337 %	187 M €
BNP Paribas Asset Management Belgium SA 0.1475 %	90,814	0.1475 %	82 M €
Sjunde AP-fonden 0.1314 %	80,902	0.1314 %	73 M €

Name	Equities	%	Valuation
Fidelity Management & Research Co. LLC 9.245 %	5,692,346	9.245 %	5 191 M €
T. Rowe Price International Ltd. 5.913 %	3,640,409	5.913 %	3 320 M €
Janus Henderson Investors US LLC 4.183 %	2,575,251	4.183 %	2 349 M €
Artisan Partners Holdings LP 3.551 %	2,186,510	3.551 %	1 994 M €
Capital Research & Management Co. (World Investors) 3.183 %	1,959,504	3.183 %	1 787 M €

List of ARGENX SE shareholders

Company details: argenx SE

argenx SE

Laarderhoogtweg 25

1101 EB, Amsterdam

+31 10 703 8441

http://www.argen-x.com

Group companies: argenx SE

Name	Category and Sector
arGEN-X BV arGEN-X BV Manufactures antibody-based medicines
arGEN-X BV arGEN-X BV Manufactures antibody-based medicines

See all subsidiaries

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ARGENX SE	-3.93%	-7.66%	+24.59%	+94.67%	54.11B
INSMED INCORPORATED	-0.05%	+0.19%	+174.91%	+911.92%	42.02B
WUXI APPTEC CO., LTD.	-3.02%	-0.37%	+61.43%	+16.56%	39.6B
BIONTECH SE	-1.05%	-3.57%	-22.07%	-48.47%	22.8B
GENMAB A/S	-0.10%	-2.09%	+39.94%	-36.01%	19.5B
WUXI BIOLOGICS (CAYMAN) INC.	-2.03%	-5.36%	+83.80%	-38.09%	17.76B
AKESO, INC.	-2.07%	-4.44%	+84.78%	+173.62%	14.73B
SUMMIT THERAPEUTICS INC.	-1.08%	-6.68%	-2.52%	+385.47%	13.55B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.24%	-6.61%	+122.07%	-	13.14B
MADRIGAL PHARMACEUTICALS, INC.	-1.91%	-1.41%	+84.09%	+791.18%	12.98B
Average	-1.46%	-2.27%	+65.10%	+250.10%	25.02B
Weighted average by Cap.	-1.77%	-2.65%	+67.10%	+251.69%